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I. INTRODUCTION 
I.1. Ion channels: general properties 
Ion channels are pore-forming, integral membrane proteins allowing the transport of inorganic 
ions down their electrochemical gradient across the cell membrane. They have three 
characteristic features: gating, selective permeability and conductance. The term gating refers 
to a transition/conformational change between different functional (open, closed) and/or 
structural (open, closed, inactivated) states upon a specific  stimulus. Ion channels can be 
classified by this special stimulus as voltage-, extracellular ligand, intracellular messenger and 
stretch-gated channels. Ion channels provide selective transport for a given ion (or group of 
ions). Based on their selectivity we distinguish highly selective, mildly selective and non-
selective ion channels.  
I.2. Structure and function of the voltage-gated Kv1.3 channel 
Kv1.3 is a voltage-gated, homotetrameric channel formed by four, 523-amino-acid-residue-
long, non-covalently bonded identical subunits. Every subunit composed of six 
transmembrane alfa-helices connected by intra and extracellular loops. Each subunit contain a 
94-amino-acid-residue-long intracellular C-terminal and a 184-amino-acid-residue-long 
intracellular N-terminal. While the transmembrane segments are highly ordered, conservative 
regions, the flexible C-terminus can take up a random coil  but not a rigid structure. Kv1.3 
subunits can assembly with other Kv isoforms (Kv1.1, Kv1.2, Kv1.4, Kv1.5) to form 
functional channels. The subunit composition determines the structural, biophysical and 
pharmacological properties of the heteromers. The Kv1.3 ion channel was described as a 
transmembrane protein of the human T cells in 1984. Comprehensive proteomic studies 
demonstrated that the Kv1.3 also expressed by other immune cells (B cells, dendritic cells) 
and in the central nervous system and gastrointestinal tract. The most widely studied function 
of Kv1.3 is the regulation of calcium signaling during T cell activation by keeping the 
membrane potential at negative values. By the use of Kv1.3-selective antagonists lymphocyte 
proliferation, migration and IL-2, IFN- production can be inhibited. Due to the specific ion 
channel expression pattern of the activated effector memory (TEM) cells, specific Kv1.3 
antagonists can be novel drugs in the treatment of the autoimmune disorders (i.e. multiple 
sclerosis, rheumatoid arthritis, type 1 diabetes) where mainly TEM cells are responsible for the 
inflammation and tissue distruction.  
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I.3. Cholesterol regulation of ion channels 
In the last few years many studies have emphasized the role of cholesterol in the regulation of 
ion channels. Because of the structural and functional variability of the ion channels 
cholesterol has distinct influence on the different channels. The general effect of cholesterol is 
usually a dose-dependent decrease in the channel activity (open probability, unitary 
conductance), which was demonstrated for many K
+ 
and also Ca
2+
, Na
+ 
channels. Contrary, 
TRP channels' activity is inhibited by the removal of cholesterol. Cholesterol can also 
modulate the kinetic and equilibrium parameters of the ion channels. Two main models 
explain the effects of cholesterol on ion channels' function. The first theory focuses on the 
direct and specific lipid-protein interactions: cholesterol is involved in the assembly of an 
annular lipid belt around the ion channel. The components of this lipid belt or shell can easily 
interact with the transmembrane helices of the ion channels which contain specific lipid 
receptors. The manipulation of the membrane cholesterol level can change the conformation 
of the ion channels via modify these specific lipid-protein interactions. Recent studies have 
demonstrated that not just the classical lipid-protein interfaces but also the intracellular C and 
N terminal can interact directly with cholesterol through cholesterol recognition sites. Several 
putative cholesterol recognition sequences have been identified, which predicts that a 
transmembrane protein is to interact with cholesterol. Among them the CRAC and CARC 
sequences were the first documented and they are considered the most significant. The CRAC 
(cholesterol recognition amino acid consensus motif) is based on a very simple algorithm: it 
begins with a branched non-polar amino acid (leucine or valine) followed by 1-5 arbitrary 
amino acids, then, through an aromatic tyrosine, 1-5 other optional amino acids precede(s) a 
positively charged amino acid (lysine, arginine) that closes the sequence. The CARC 
sequence is the 'inverse' of the CRAC. It starts with a positive amino acid and, along with 
tyrosine, the closing aromatic amino acid can be phenylalanine, too. Due to the simplicity of 
the algorithm, the sterol sensitivity of proteins with CRAC/CARC sequence should be treated 
with careful skepticism, it only may serve as a predictive tool. However, we cannot ignore the 
results according to which a simple point mutation or deletion of these motifs could totally 
alter the cholesterol sensitivity of wild-type ion channels.  
From another point of view, the cholesterol can influence the ion channels’ operation 
via changing the physical parameters of the cell membrane. Due to the difference in the 
thickness of the hydrophobic parts of the transmembrane proteins and the lipid bilayers, the 
protein perturbs the surrounding lipids, thus changing the thickness and the order of the 
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bilayer. The bilayer adjusts its local thickness equals to that of the hydrophobic region of the 
transmembrane protein. During the conformational change, such as activation of an ion 
channel, the proteins deform the surrounding lipid bilayer: the stronger the resistance of the 
membrane is, the more energy is needed for this process to occur. The modification of the 
physical parameters of the lipid environment can change the molecular movements via 
modifying the energy required for the process. The cholesterol molecules affect the fluidity, 
thickness and permeability of the membrane along with the lateral diffusion of the membrane 
protein, and thus they can influence kinetic and equilibrium parameters of the ion channels’ 
conformational change. These two models do not exclude each other, but the influence of the 
individual mechanisms (direct vs. indirect sterol effect) can differ from a channel to another. 
The separation of two effects for a particular channel provides researchers with a challenge. 
A possible method is based on the investigation of cholesterol analogues whose impact 
on the membrane is similar to that of the cholesterol but cannot replace it in the specific 
sterol-protein interaction. The epicholesterol and the ent-cholesterol are two chiral cholesterol 
analogues that, with minor divergence, meet the abovementioned criteria. While the 
cholesterol decreases the Kir.2.1 channel’s current density, epicholesterol increases it, 
indicating a specific lipid-protein interaction. Stereo-specificity of  cholesterol analogues have 
been reported in the case of BK and TRPV1 channels, while nAchR or VRAC channels didn’t 
not show any difference in the impact of the optical isomers and the cholesterol.  
I.4. The prototype of cholesterol biosynthesis disorder-Smith Lemli-Opitz syndrome 
In the last 30 years it has been revealed about several malformation syndromes (Smith-
Lemli-Opitz syndrome, lathosterolosis, desmosterolosis) that they are caused by sterol synthesis 
error. The first one that has been documented is the Smith-Lemli-Opitz syndrome (SLOS), which 
was named after the medical doctors described it in 1964. The SLOS is an autosomal recessive, 
monogenetic malformation syndrome. The syndrome is caused by the deficiency of 7-
dehydrocholesterol reductase (7-DHCR), which catalyzes the last step of the Kandutsch–Russell 
pathway. 
Apart from decreasing the cholesterol level, the enzyme defect elevates the level of the 
precursor molecules of the cholesterol synthesis (most importantly 7-dehydrocholesterol (7DHC) 
and 8-dehydrocholesterol) both in the blood plasma and the cell membrane. As a result of the 
process, the composition of the lipid rafts and the membranes changes, different signaling 
pathways suffer from disorder, and the cholesterol as a universal precursor molecule (bile acids, 
neuroactive steroids, steroid hormones) cannot fulfill its task entirely either. However, it is still 
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an unanswered question, whether it is the lack of cholesterol or the toxic effect of the precursor 
molecules that are primarily responsible for the development of the symptoms. 
The symptoms and occurrence of the disease are diverse: besides the frequent 
developmental disorders of the face and the head-neck region, almost all organ systems can be 
affected. The disease was originally described on the basis of the clinical phenotype as the 
simultaneous presence of facial dysmorphia, microcephaly, hypospadias and somatomental 
retardation by Smith, Lemli and Opitz. Besides the characteristics indicators of SLOS, the 
infant’s abnormally slow weight-gain and feeding problems can draw the doctor’s attention to 
the disease. Frequent consequences are the respiratory system’s various bacterial and viral 
infections, which are rather caused by secondary factors (the anatomic deformation of the head-
back region, the immobility of the patients, the hypotonia of the respiratory muscles) than the 
immunosuppression accompanying the disease. When clinical SLOS suspicion arises, it can be 
confirmed by the serum cholesterol decrease and the elevated 7DHC level. Further verification 
can be provided by molecular genetic testing. More than 130 different mutations of 7DHCR have 
been identified so far, but there is no tight genotype-phenotype correlation, thus the same 
mutation can lead to either serious or minor disorders. The patients’ categorization in terms of 
the disease’s seriousness is carried out with the help of the phenotype signs-based Bialer point 
system modified by Kelley and Hennekam. For the treatment of the disease only symptomatic 
therapies are available at present. Oral cholesterol substitution has been reported to improve 
behavioral problems and hearing functions, along with causing less photosensitivity and less 
infections. The antioxidant treatment and the statin therapy can be effective through the 
reduction of the sterol precursors’ toxicity. Opinions differ about the effectivity of these 
treatments, since randomized, placebo controlled clinical studies have either yet to be done or 
they don’t support the discrepancies found in non-standardized studies. There is no data about 
the incidence of the disease in Hungary yet, but the estimated values (1:10000-1:70000 or 
according to a recent research 1:39125) suggest that it is significantly underdiagnosed. The 
SLOS samples we investigated are from the previously characterized Hungarian patients. 
I.5. Hypercholesterolemia and its immunological aspects 
Hypercholesterolemia (HC), which develops during hyperlipidemia, is just a symptom. Three 
main reasons can be found in the background: overburdened metabolism due to the unhealthy 
diet and lifestyle; secondary metabolism disorders caused by diseases or medications; the 
primal, inherited disorders of lipid metabolism. In addition to cholesterol, the concentration of 
other lipids and lipoproteins also change, thus, along with etiology, the abnormalities can be 
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categorized according to the Fredrickson classification, which considers the lipoprotein 
concentration, or on the basis of the triglyceride and the cholesterol level. 
The consequences of hypercholesterolemia can be, irrespective of etiology and 
classification, systemic arteriosclerosis, heart attack, stroke, or peripheral vasoconstriction. The 
effective treatment of hyperlipidemias is based on a suitable diet and a lifestyle change, which, in 
most cases, can be completed with the use of statin medications that selectively block the key 
enzyme of cholesterol biosynthesis called hydroxy-metil-glutanyl-CoA(HMGCoA).  
We cannot overemphasize the general importance of hyperlipidemia, since in the 
developed countries more than 50 percent of the adult population have an abnormal lipid profile, 
and the accompanying diseases place a significant burden on the healthcare system. Although the 
recent years have shown a slight improvement, cardiovascular diseases are still the number one 
cause of death in Hungary. An intensive basic research have brought about in the past few years 
that unveiled the pathogenesis of atherosclerosis at molecular and cellular level. According to the 
most widely accepted hypothesis, arteriosclerosis is a chronical inflammatory reaction to the 
various damages of the endothelial cells, which are caused by mechanical stress, metabolic 
disorders, infections or smoking. The build-up of lipid (including cholesterol) molecules in the 
artery wall plays a significant role in maintaining the inflammation. The inflammatory factors 
produced by the damaged endothelium activate the inborn and adaptive immune system’s cells, 
which, along with the smooth muscle cells, participate in the creation of atherosclerotic plaques 
saturated mainly with cholesterol. The plaque does not only block the vessels, but the detached 
fragments can also cause microemboli. On the top of that aneurysm frequently occurs in the 
weakened blood vessel wall, whose cracking can cause serious bleeding. It seems that T-cells 
play a prominent role in the inflammatory processes of arteriosclerosis. Both in human patients 
and model animals suffering from atherosclerosis the presence of activated T-cells in 
arteriosclerotic plaques was reported. A significant group of the T-cells was specific to oxidized 
lipid molecules. In hyperlipidemic animal models the depletion of CD4
+
 lymphocytes reduced 
the progression of arteriosclerosis, while in immune deficient SCID mice the restoration of 
immunologic functions sped up the process. It is an important discovery, that the conditions 
leading to arteriosclerosis can also influence the normal functioning of the immune system, 
reducing its resistance towards various pathogens. The plasma hypercholesterinemia increases 
the cholesterol content of the lymphocytes’ cell membrane. In the animal models the artificially 
generated hypercholesterinemia negatively influenced the physiological functions attributed to 
Kv ion channels. To our best knowledge, our work team has been the first to document the effect 
8 
 
of increased plasma hypercholesterinemia in the case of Kv1.3 channels in lymphocytes isolated 
from humane samples. 
II. OBJECTIVES 
In the recent years several studies have been published that characterize cholesterol as 
an important regulator of the ion channel function. In these studies the membrane cholesterol 
content was usually altered by in vitro methods (e.g. cyclodextrin-cholesterol complex), then 
the researchers investigated the impact of the altered environment on the ion channels. 
According to the previous results of our laboratory, the in vitro elevated cholesterol level 
modifies the gating of the Kv1.3 ion channels in lymphocytes isolated from healthy donors. 
As a result of the treatment, the activation and inactivation kinetics slowed down, and the 
equilibrium activation of the channel shifted towards the more positive membrane potentials. 
Similar changes have been described for calcium ion channels, too. One of the principal 
questions of our present work is whether the modifying role of sterols seen in in vitro 
experiments has any biological significance. Does any disease exist where the altered 
cholesterol content of the cell membrane influences the regulation of the ion channels? To 
answer this question, we studied the effect of  two diseases (hypercholesteraemia and 
cholesterol synthesis disorder), which significantly but oppositely affect the cholesterol 
homeostasis, on the ion channels and function of T-cells isolated from peripheral blood. 
Only little information is available about the function of the C-terminal of Kv1.3 
channel.  According to our hypothesis, the C-terminal of Kv1.3 can participate in the 
interaction of the channel with sterols, similarly to other ion channels (e.g. P2X7 and BK 
channels) Upon the investigation of the amino acid sequence of Kv1.3, we mapped several 
CARC cholesterol recognizing motifs in the C-terminal of Kv1.3. In our experiments we 
investigated the role of the C-terminal of Kv1.3 in the interactions with sterols. 
 
In our work with focused on the following goals: 
 
I. Analysis of  the cholesterol content and the sterol profile of cells isolated from patients 
with hypercholesterinemia and Smith-Lemli-Opitz syndrome  
II. Determine the gating parameters of Kv1.3 ion channels in lymphocytes isolated from 
patients with hypercholesterinemia or Smith-Lemli-Opitz syndrome 
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III. To explore the impact of the in vitro altered membrane cholesterol content on the T-
lymphocyte functions regulated by ion channel (activation, proliferation)  
IV. To model the membrane 7DHC content specific for SLOS in lymphocytes isolated 
from healthy donors  
V. To study the biophysical features of Kv1.3 ion channels in the SLOS model system 
VI. To compare the effects of cholesterol and by 7DHC on the Kv1.3 ion channel  
VII. To examine the cholesterol and 7DHC sensitivity of the C-terminal deleted Kv1.3 ion 
channel 
VIII. To reveal the cholesterol sensitivity of mutant channels with mutation in the CARC 
sequences located in the C-terminal of Kv1.3  
III. MATERIALS AND METHODS 
III.1. Reagents 
All reagents were purchased from Sigma-Aldrich (Budapest, Hungary), unless stated 
otherwise. 
III.2. Patients 
III.2.1. Smith-Lemli-Opitz szindróma 
Eight SLOS (age: 7.65±2.23 years) and eight age-matched control patients from Hungary 
(age: 7.66±1.83 years) were enrolled in the study.  
III.2.2. Hypercholesterinaemia 
The present study was performed on 7 healthy and 20 previously untreated type II/A and II/B 
hyperlipidemic patients. Hyperlipidemic patients were divided into two groups on the basis of 
total cholesterol level: slightly elevated hypercholesterolemic (5.2 mM < [total serum 
cholesterol] < 10 mM) and markedly elevated hypercholesterolemic groups ([total serum 
cholesterol] > 10 mM).  
III.3. Cells 
III.3.1. Mononuclear cells 
Mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation. Cells 
were washed twice with Ca
2+
- and Mg
2+
-free Hanks’ solution containing 25 mM HEPES (pH 
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7.4). Freshly isolated cells were used for CFSE-assay and the remaining mononuclear cells 
were frozen and stored at -80 
o
C until patch-clamp and CD154 expression experiments. 
III.3.2. CHO (Chinese Hamster Ovary) cell line 
CHO cells (ATCC, Germany) were cultured in DMEM medium, which also contained 10 % 
FBS, L-glutamine (2 mM), penicillin (100U/l), and streptomycin (100 mg/l). Cells were 
maintained at 37 °C in a humidified atmosphere of 5% of CO2 and 95% air. Cells were passed 
every 2–3 days. CHO cells were transduced with retroviral particles containing mGFP-Kv1.3-
WT and mGFP-Kv1.3ΔC constructs as described in (6).  
III.4. 7DHC and CHOL loading of T cell membrane 
Freshly isolated control (healthy) lymphocytes were washed twice with Hanks’ solution and 
suspended in Hanks’ solution (2 × 106 cells/ml) containing different concentrations of methyl-
-cyclodextrin/7-DHC (MCD/7DHC, CycloLab Cyclodextrin Research and Development 
Laboratory Ltd. , Hungary) or methyl--cyclodextrin/cholesterol (MCD/CHOL, CycloLab 
Cyclodextrin Research and Development Laboratory Ltd. , Hungary). In control experiments 
MCD/7DHC, MCD/C was not present in the solution. Cell suspensions were incubated for 
1 h at 37 
oC and washed three times with Hanks’ solution. 
III.5. Analysis of the cholesterol and 7-dehidrocholesterol levels of cells 
III.5.1. Amplex Red Cholesterol Assay Kit  
The cholesterol level of control and hypercholesterolemic cells was determined using Amplex 
Red Cholesterol Assay Kit according to the instructions of the manufacturer, and fluorescence 
was detected using Multimode Microplate Reader (BioTek, Winooski VT).  
III.5.2. Analysis of the sterol composition of red blood cells using GC-MS 
Gas chromatography-mass spectrometry (GC-MS) experiments were carried out by use of the 
standard protocols to define sterol composition of red blood cells isolated from SLOS. All of 
the GC-MS experiments were carried out by our collaborator, Mária Péter in Szeged. 
Identification was made based on CHOL and 7DHC standard solutions.  
III.6. Electrophysiology 
Whole-cell measurements were carried out using Axopatch-200A/B amplifiers connected to 
personal computers using Axon Digidata 1440 digitizers. For data acquisition and analysis the 
pClamp10 software package (Molecular Devices, Sunnyvale, CA) were used. CD4
+
T 
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lymphocytes were selected for current recording by incubation with mouse anti-human CD4 
antibodies (0.5 µg/106 cells, AMAC, Westbrook), followed by selective adhesion to petri 
dishes coated with goat anti-mouse IgG antibody (Biosource, Camarilo, CA), as described 
previously (5). Standard whole-cell patch-clamp techniques were used, as described 
previously (1). Pipettes were pulled from GC 150 F-15 borosilicate glass capillaries (Clark 
Biomedical Instruments, UK) in four stages and fire-polished to give electrodes of 3–6 M 
resistance in the bath. The standard bath solution (S-ECS) was (in mM): 145 NaCl, 5 KCl, 1 
MgCl2, 2.5 CaCl2, 5.5 glucose, 10 HEPES (pH 7.35, 305 mOsm). The pipette solution was (in 
mM): 140 KF, 11 K2EGTA, 1 CaCl2, 2 MgCl2, and10 HEPES (pH 7.20,295 mOsm). To 
study activation kinetics of Kv1.3 T cells were depolarized to 50 mV for 15 or 30 ms from a 
holding potential –120mV. Kv1.3 current traces were fitted with a single exponential function 
rising to the maximum according to the Hodgkin-Huxley model (I(t) = Ia (1exp(t/a))
4
 + 
C, where Ia is the amplitude of the activating curve component;a is the activation time 
constant of the current; C: current amplitude at –120 mV). The activation time constant for a 
particular cell was defined as the average of time constants obtained for at least 3 depolarizing 
pulses repeated at every 15 s in a sequence. We recorded at least four cells of a given patient 
or donor, and the average of the activation time constants was used to demonstrate the 
activation kinetics. To study the inactivation of Kv1.3 channels, two-second-long step pulses 
to +40 mV from a holding of -120 mV were applied to the cells. The fast activation of 
outward current is followed by a relatively slow decay of current corresponding to the C-type 
inactivation of this channel. The decaying part of the current traces was fitted with a single 
exponential function (I(t) = I0 exp(-t/in,i) + C, I0: amplitude of current,𝜏in,i: inactivation time 
constant for different groups, C: steady-state value of whole-cell current at the end of the 
pulse) to attain the time constant characterizing the inactivation kinetics. The characteristic 
inactivation time constant for a given cell was determined as detailed for the activation 
kinetics. Membrane potential dependence of steady-state activation of the Kv1.3 current was 
determined as follows: cells were held at 120 mV and depolarized to gradually increasing 
test potentials. Peak whole-cell conductance (G(V)) at each test potential was calculated from 
the peak current (Ipeak) at a test potential V and the K
+
 reversal potential (EK) using G(V) = 
Ipeak/(Vtest-Er). The G(V) values were normalized for the maximum conductance (Gnorm) and 
plotted as a function of test potential along with the best-fit Boltzmann function (Gnorm = 
1/(1+exp [ (VV½)/k], where Gnorm is the normalized conductance, V is the test potential, 
V½is the midpoint and k is the slope of the function). We calculated the steady-state 
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parameters at least four individual cells from each donor. The whole-cell membrane 
capacitance (C) setting on the amplifier required to cancel the transient charging currents 
evoked by periodic application of 5mV test pulses was considered as the membrane 
capacitance of the cells. 
III.7. CD154 expression detection 
Previously isolated control and SLOS mononuclear cells were stimulated with thapsigargin (1 
µM) for 3 hours at 37C. For flow cytometry, cells were labeled with phycoerythrin 
conjugated mouse anti-CD3 antibody (PE-CD3) and Alexa-488 conjugated mouse anti-
CD154 antibody (A488-CD154) and there isotype control for 20 minutes at room temperature 
according to the manufacturer’s protocol (Biolegend; San Diego; CA). After the staining 
procedure, the fluorescence intensity of T cells was assessed by BD FacsScan flow cytometer 
(Beckton-Dickinson, NJ, USA). In all experiments, at least 10000 events were recorded and 
analyzed using FCS Express 4 software (De Novo Software, Glendale, USA).  
III.8. CFSE staining and analysis  
To study proliferation of lymphocytes, we applied the carboxyfluorescein succinimidyl ester 
(CFSE) dilution essay, originally described by Lyons et al (2-4). The final concentration of 
CFSE (CellTrace™ CFSE Cell Proliferation Kit, Life Technologies Co., Waltham, MA, 
USA) was 1µM that. After adding CFSE, we incubated the peripheral blood mononuclear 
cells (PBMC) for 15 minutes at room temperature, then for 20 minutes at 37°C. Lastly, the 
cells were washed once with PBS. We applied 500 ng/ml soluble anti-CD3 antibodies 
combined with 1 µg/ml soluble mouse anti-human CD28 for specific T cell stimulation in the 
mononuclear cell cultures. The flow cytometry analysis was performed on a BD FACScan™ 
cytometer. We measured the forward scatter (FSC), side scatter (SSC) and the fluorescence 
intensity in the green. Lymphocytes were selected from mixed cell populations of PBMC by 
their light scatter profile on FACS analysis. Cell proliferation was determined based on the 
decreasing CFSE intensity in the green channel. The indicator of proliferation was the 
division index (DI), calculated by the formula: 
𝐷𝐼 = (∑𝐴𝑘
𝑛
𝑘=1
) /(∑𝐴𝑘
𝑛
𝑘=0
) 
where k points to the n
th
 generation of cells, and Ak is the cell number in the k
th
 division cycle 
according to.  
13 
 
III.9. Flanking primer mutagenesis 
We applied modified version of flanking primer mutagenesis to generate point mutations in 
the wild type Kv1.3. 
III.9.1. Polymerase chain reaction (PCR) 
Phusion High-Fidelity DNA Polymerase enzyme was applied according to the 
manufacturer protocols (Thermo Fisher Scientific, Inc., Waltham). The following forward and 
reverse primers were used: 
 
CARC4 binding site 
forward: 
5’GCGGTATCGGAGGCTGCGTGAGTCTCAGCTCAATGAGGA 
reverse: 
5’GCGTCGGAGGCTATGGCGATCGAAGAGGGGGGTATGAAC 
 
CARC5 binding site 
forward: 
5’ AGCATCGGTGGCTATCGCTGCGATGTTGACACAAGAGTTGGG 
reverse: 
5’ GCAGCGATAGCCACCGATGCTTAAGCGGCCGCGAATTCTGCAGTC 
III.9.2. Agarose gel electrophoresis 
PCR products were separated in 1% agarose gels supplied with 0.5 µg/ml ethidium 
bromide. Gel tank was filled with 1xTAE buffer and the gel run at 100V for 30 min. DNA 
fragments were cut out under an UV transilluminator.  
III.9.3. DNA extraction and purification 
Traditional phenol extraction method was used to extract and purify DNA fragments.  
III.9.4. Restriction digestion 
Eco91I (GAATT↓C) and EcoRI (G↓GTAACC) restriction enzymes (Thermo Fisher 
Scientific, Inc., Waltham, USA) were applied according to the manufacturer’s protocol.  
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III.9.5. Ligation, transformation, plasmid preparation   
We used T4 DNA Ligase (Thermo Fisher Scientific, Inc., Waltham) for ligation with 
1:5 vector:insert molar ratio. Circular plasmids were added to 200 L E. coli (ET12567) 
component cell solution and incubated on ice for 20 minutes. Next, 42°C heat shock was 
applied for 1 min., finally cells were placed on ice for 2 min. Samples were suspended in 
800µl SOC medium and cultured at 200 rpm and 37°C for 50 min in a shaking incubator. In 
the next step bacteria were spread onto LB agar plates containing 50 µg/ml kanamycin and 
incubated overnight, at 37°C. A single colony of transformed bacteria was inoculated into LB 
medium containing antibiotic and was grown at 37°C, 200 rpm overnight. PureYield Plasmid 
Miniprep System (Promega Corporation, USA) was used to purify plasmid DNA.  
III.10. Data analysis 
 Prior to analysis whole-cell current traces were corrected for ohmic leak. Non-linear 
least squares fits were done using the Levenberg-Marquardt algorithm. Fits were evaluated 
visually as well as by the residuals and the sum of squared differences between the measured 
and calculated data points. Data are expressed as mean ±SEM. For pairwise comparisons 
Student's t-test or Mann–Whitney rank sum test (non-normally distributed populations) were 
applied. For multiple comparisons one-way or two-way ANOVA with post-hoc Holm-Sidak 
(HS) test were used. Statistical significance was taken as p<0.05.  
 
 
IV. RESULTS 
IV.1. Cholesterol content of lymphocytes in hypercholesterolemia 
It has been previously demonstrated, that hypercholesterinemia increased the cholesterol 
content of T cells. To prove these results, we determined the cholesterol content of 
lymphocytes isolated from healthy donors and HC patients. To validate our technique, we 
introduced a positive control: normocholesterolaemic lymphocytes were loaded with 
cholesterol complexed to methyl--cyclodextrin (MCD/C) at concentration of 1.5 mg/ml. 
The cholesterol concentration of samples from three different hypercholesterolaemic patients 
of group II is higher than the control value (control: 0.66 ± 0.009 µg/ml, n=3, group II: 0.91 ± 
0.07 µg/ml, n=3, p<0.001). However, cholesterol loading using 1.5 mg/ml MCD/C could 
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raise the cholesterol content of lymphocytes to a higher value than in cells obtained from 
group II of hypercholesterolemic patients (1.5 mg/ml MCD/C: 1.53 ± 0.03 µg/ml, n=3, 
p<0.001). 
IV.2. Expression of Kv1.3 channels in CD4+ T lymphocytes in hypercholesterolemia 
According to our previous study, in vitro cholesterol loading of lymphocytes decreases the 
Kv1.3 expression. Based on this, we hypothesized that the increased cholesterol content of 
hypercholesteremic T cells decrease  the Kv1.3 expression. The expression level of Kv1.3 
channels was measured by whole-cell current amplitudes (WCC) upon depolarization to + 50 
mV for 15 ms from a holding potential of –120 mV. Current amplitudes were not different in 
control and hypercholesterolemic groups (WCCc= 642.1 ± 44.3 pA, n=51, WCCGI= 631.9 ± 
48.2 pA, n=57, p=0.74; WCCGII= 620.2 ± 37.4 pA, n=42, p=0.74). Hypercholesterolemia did 
not change the whole cell membrane capacitance of CD4
+
 T lymphocytes (Cm,c= 1.68 ± 0.17 
pF, n=31, Cm,GI= 1.67 ± 0.12 pF, n=46, p=0.96; Cm,GII= 1.54 ± 0.09 pF, n=42, p=0.48). The 
peak current normalized to membrane capacitance (current density, CuD) was calculated for 
each cell individually, which is the peak current at +50 mV divided by the membrane 
capacitance for each cell and these values were averaged for each group. Comparing the 
current densities we found no significant difference between normal and 
hypercholesterolemic CD4
+
 T cells (CuDc= 499.3 ± 65.4 pA/pF, n=39, p=0.49; CuDGI= 450.7 
± 41.7 pA/pF, n=46, p=CuDGII= 478.1 ± 45.6 pA/pF, n=42, p = 0.78). There was no 
significant difference between the CuD of Group I and II (p=0,708). 
IV.3. Kinetic parameters of Kv1.3 gating in hypercholesterinemia 
Lymphocytes were depolarized to + 50 mV for 15 ms from a holding potential of –120 mV. 
The activation kinetics of Kv1.3 current was fitted with a single exponential function rising to 
the maximum according to the Hodgkin-Huxley (HH) model (I(t) = Ia  (1-exp(-t/a))
4
 + C) 
where Ia is the amplitude of the activating current component; a is  the activation time 
constant of the current; C: current amplitude at –120 mV). The activation time constant for a 
particular cell was defined as the average of time constants obtained for at least three 
consecutive depolarizing steps repeated at every 15 s. The activation kinetics of the whole-
cell current was significant faster only in group II compared to control (a,c = 0.811 ± 0.028 
ms, n=51, a,GI =0.731 ± 0.028 ms, n=47, a,GII = 0.724 ± 0.024 ms, n=41, p=0.02). At 0 mV 
test potential, where the activation kinetics of the current is slower due to the inherent 
voltage-dependence of Kv1.3 gating we found significant acceleration of the activation 
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kinetics also in group I and II T cells compared to normocholesterolemic control. (a,c = 2.28 
± 0.13 ms, n=50, a,GI = 1.86 ± 0.09 ms, n=48, a,GII = 1.79 ± 0.08 ms, n=40 p=0.002) . To 
study the inactivation kinetics of Kv1.3 current the decaying part of the current traces was 
fitted with a single exponential function (I(t) = I0 exp(-t/i,x) + C, where I0 is amplitude of 
current, i,x, is the inactivation time constant of the current in group x and C is steady-state 
value of whole-cell current at the end of the pulse) to obtain  the time constant characterizing 
the inactivation kinetics. The inactivation time constant characteristic for given cell was 
defined as the average of time constants obtained for at least three consecutive depolarizing 
steps repeated at every 60 s. The inactivation was faster in hypercholesterolemic state but the 
statistical comparison did not show significant change versus control. (i,c = 243.8 ± 8.0 ms, 
n=41; i,GI = 229.3 ± 6.9 ms, n = 48; i,GII =  234.9 ± 8.2 ms, n = 35, p = 0.43).  
IV.4. Steady-state parameters of activation  
In our previous study the in vitro cholesterol loading resulted in a rightward shift of the steady 
–state activation. Two parameters, the midpoint (V1/2) and the slope factor (k) were used to 
characterize the steady-state activation. Our results showed that neither the midpoint of 
voltage dependence of steady-state activation (V1/2,control = 24.9 ± 0.87 mV, n=26, V1/2,GI= 
26.5 ±1.0 mV, n=38, p=0.25; V1/2,GII = 26.1 ±0.9 mV, n=27, p=0.43) nor the slope factor 
of steady-state activation (sc=10.8 ± 0.35, n=26, sGI= 10.4 ± 0.22, n=38, p=0.32; sGII= 10.0 
± 0.26, n=27, p=0.07) was different among the control, group I and group II T cells. 
IV.5. T cells in hypercholesterolemia show higher basal proliferation rate  
T cell proliferation rate was determined using CFSE staining method (see Material and 
Methods) after antiCD3/antiCD28 stimulation. Our data shows that the antiCD3/antiCD28 
stimulation of T lymphocytes was less effective in hypercholesterolemic state than that in the 
control group. The precursor frequency was 71.8 ± 10.2 % (n=10) in control group, 40.9 ± 5.1 
% (n=7) in group I and 46.0 ± 5.0 % (n=11) in group II. 
IV.6. Sterol composition of SLOS membrane 
The Amplex-Red assay cannot differentiate between cholesterol and its oxidized forms. 
Therefore we applied GC-MS technique to characterize sterol profile of the red blood cells 
(RBC) from SLOS patients and age-matched control. Analysis of the sterol composition of 
the T lymphocyte cytoplasmic membrane was not possible due to the limited amount of the 
blood samples. On the other hand, erythrocytes do not have intracellular membrane systems, 
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hence, various CHOL precursors can only be incorporated into the plasma membrane. 
Therefore, the total sterol in RBCs should provide us with a good estimate of the sterol 
composition of the cytoplasmic membrane of other cells as well. In line with the previous 
results, we could identify elevated 7DHC and reduced CHOL levels in all of the SLOS 
samples, while 7DHC in the control samples was undetectable. 8DHC, which is a common 
isomer of 7DHC, was also identified in every SLOS sample. Results of the RBC sterol 
composition analysis are comparable to the comprehensive study by Russo et al (data not 
shown).  
IV.7. Expression level of Kv1.3 channels in SLOS T cells is similar to that in healthy 
donors  
In SLOS the reduced cholesterol levels associated with the increased concentrations of the 
precursor molecules of cholesterol synthesis (7DHC, 8DHC). The altered sterol composition 
of the cell membrane could modify the ion channel function. So far, there is no information 
about the effects of these SLOS derived precursors on Kv channel operation. Consequently 
we examined the expression and biophysical properties of Kv1.3 channels in SLOS patients. 
Current density (CuD: the peak current normalized to membrane capacitance, proportional to 
the number of channels per unit area) provides information about the impact of the channels 
on the membrane potential control of the cell, since a given number of channels regulate the 
membrane potential more readily in a smaller cell than in a larger one. T cells were held at –
120 mV (holding potential) and depolarized to +50 mV for 15 ms in whole-cell configuration 
to determine whole cell peak currents (Ip), then Ip of an individual cell was divided by the 
membrane capacitance (C) of the particular cell to calculate current density. Whole-cell peak 
currents and whole-cell membrane capacitance were the same in control and SLOS groups 
(Ip,control = 528.0 ± 69 pA, n = 56, 8 donors; Ip,SLOS = 497.5 ± 31 pA, n = 51, 8 patients, p = 0.7 
; Ccontrol = 2.1 ± 0.1 pF, n = 56, 8 donors; CSLOS =2.0 ± 0.2 pF; n= 51, 8 patients, p = 0.69 
).There was no statistical significant difference between the current densities of control and 
SLOS T cells (CuDcontrol = 282.5 ± 42.9 pA/pF, n = 56, 8 donors; CuDSLOS = 309.8 ± 39 
pA/pF, n = 51, 8 patients, p = 0.65). 
IV.8. Slowing of Kv1.3 current kinetics in SLOS T cells 
The activation time constant (a), and inactivation time constant (i) were determined as we 
mentioned previously (see Materials and Methods). We found that the activation time 
constant was significantly greater for SLOS cells (a,control=0.59 ± 0.02ms, n = 56, 8 donors; 
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a,SLOS = 0.75 ± 0.03ms, n = 51, 8 donor; p = 0.001), i.e. the kinetics of channel opening is 
slower in SLOS lymphocytes. In case of the inactivation we could not detect significant 
difference between SLOS and control cells increase (i,control = 227.8 ± 14.2, n = 38, 8 donors; 
i,SLOS = 253.7 ± 21.4, n = 45, 8 patients, p=0.329).  
IV.9. SLOS modifies the membrane potential-dependence of steady-state activation  
As the kinetics of the Kv1.3 gating was affected by the increased 7DHC level, we also 
investigated the equilibrium parameters of Kv1.3 activation. Test potential (V)-dependence of 
the normalized conductance (Gnorm) elucidates the ratio of the open and closed channel pools 
at a given membrane potential, i.e. assesses the steady-state activation vs. membrane potential 
relationship (for details see Materials and methods). Comparison of the equilibrium activation 
parameters showed that the midpoint of the curve (V1/2, the membrane potential at which 50% 
of the channels is open at steady-state) is significantly more positive for SLOS T cells (V½, 
control= –26.9 ± 0.9 mV, n = 41, 8 donors; V½,SLOS = –22.0 ± 1.9 mV, n = 35, 8 patients; p = 
0.03), without a statistically significant change in the slope factor (kcontrol = 11.7 ± 0.5 mV, n 
=41, 8 donors; kSLOS =10.6 ± 0.5, 8 patients; p=0.14). 
IV.10. Activation and proliferation of SLOS T cells is suppressed 
We aimed to study the effects of the altered CHOL/7DHC ratio on the Kv1.3-dependent 
biological functions of T cells such as activation and proliferation. To assess the effect of 
SLOS on T cell activation, we measured the expression of CD154 of lymphocytes. CD154 is 
a marker of activation on T lymphocytes stimulated through calcium-triggered NFAT 
pathways. We assumed that the modified ion channel function in SLOS influences the Kv1.3-
dependent calcium signaling during T cell activation, which could change the expression of 
CD154. Our results indicate that the ratio of CD154
+
 T cells decreased significantly in SLOS 
compared to the age-matched healthy controls (fraction of CD154
+
CD3
+
cells in SLOS: 8.6 ± 
3.2%, 5 patients; control: 21.1 ±2.8%, 4 donors, p<0.001). We also tested the proliferation 
capacity of T cells using the CFSE staining technique, which is a suitable method to observe 
the proliferation characteristics of lymphocytes with flow cytometry. We found that the five-
day antiCD3/antiCD28 stimulation (see details in Materials and Methods) of T lymphocytes 
was less effective in SLOS than in the control group. The division indices/indexes of T 
lymphocytes were 29.4 ± 3.5% (n = 6) and 61.1 ± 7.1 % (n = 5) for SLOS and the control 
group, respectively (p = 0.002). 
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IV.11. Modeling the SLOS sterol environment in T cells 
In order to verify if 7DHC incorporation into the T cell membrane affects Kv1.3 function, we 
created an SLOS-like sterol environment by modification of the 7DHC content of healthy T 
cells with MβCD/7DHC complex in vitro. To validate the incorporation of 7DHC into the 
plasma membrane, untreated and MβCD/7DHC treated PBMCs were subjected to GC-MS 
analysis. We applied 140M MβCD/CHOL as a positive control for sterol-loading of the 
cells. We found that the amount of 7DHC in the cell membrane increases gradually with the 
higher applied concentration of MβCD/7DHC (7DHC level normalized to protein content was 
26.1±1.00 g/mg for 65M MCD/7DHC and 66.8±11 g/mg for 195M MCD/7DHC). 
Parallel to the increase in MβCD/7DHC, the CHOL content showed decreasing tendency, 
which can be due to the CHOL removal by the empty MβCD, but the change was not 
significant as compared to the untreated group (CHOL level normalized to protein amount 
was 18.3 ± 3.7 g/mg for control, 16.2±0.2 g/mg for 65M MCD/7DHC; 13.3±2 g/mg 
for 195M MCD/7DHC). Thus, MβCD/7DHC-treated T lymphocytes reproduce the sterol 
environment found in SLOS, consequently, these T-cells can serve as a model for SLOS 
conditions. 
IV.12. Biophysical properties of Kv1.3 in 7DHC-loaded T cells resemble those observed 
in SLOS 
Next we characterized the kinetic and equilibrium parameters of Kv1.3 gating in the 7DHC-
loaded T cells. First, the activation kinetics of Kv1.3 channels was measured for 7DHC-
loaded cells and we found that activation kinetics became slower as the 7DHC level increased 
in the membrane (a  = 0.59 ± 0.02 ms for control (n=56); 1.76 ± 0.18 ms for 32.5M 
MCD/7DHC (n=7), p < 0.001; 2.04 ± 0.15 ms for 65 M MCD/7DHC (n=11), p<0.001; 
2.70 ± 0.26 ms for 195 M MCD/7DHC (n=11), p<0.001). For the inactivation kinetics, we 
found that the time constant increased compared to untreated cells (i =227.8 ± 14.2 ms for 
control (n = 38); 318.57 ± 22 ms for 32.5M MCD/7DHC (n = 5), p = 0.064, 339 ± 57 ms 
for 65M MCD/7DHC (n = 6), p = 0.02; 362 ± 26.4 ms for 195M MCD/7DHC (n = 5), 
p<0.01). Finally, the voltage-dependence of steady-state activation was evaluated for T cells 
treated with different amounts of MβCD/7DHC: just as described for SLOS cells, the 
midpoint of activation, i.e. the half-maximal voltage was shifted to the positive voltages (V½ 
was −26.9 ± 0.9 mV for control (n = 41); −19.2 ± 1.3 mV for 32.5M MCD/7DHC (n = 6), 
p<0.01; −13.4 ± 2.6 mV (n = 9) for 65M MCD/7DHC, p<0.001; −10.1 ± 1.9 mV for 
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195M MCD/7DHC (n = 9), p<0.001) unlike the slope factor, which was the same for all 
treatments (k = 11.7 ± 0.5 mV for control (n = 41); 11.07 ± 0.11 mV for 32.5M 
MCD/7DHC (n = 6), p = 0.53; 12.48 ± 0.56 mV for 65M MCD/7DHC (n = 9), p = 0.34; 
13.58 ± 0.80 mV for 195M MCD/7DHC (n = 9), p = 0.03). Current density, whole-cell 
peak current and membrane capacitance (see above) were also determined for 32.5, 65, and 
195 M MCD/7DHC treatments. Although membrane capacitance did not change, the 
whole-cell peak currents decreased significantly upon the 7DHC loading (C was: 2.12 ± 0.12 
pF for control (n = 51); 2.20 ± 0.22 pF for 32.5M MCD/7DHC (n = 7), p = 0.80; 2.02 ± 
0.29 pF for 65 M MCD/7DHC (n = 11), p = 0.81; 2.26 ± 0.21 pF for 195 M 
MCD/7DHC (n = 11), p = 0.65; Ipwas: 527.7 ± 68.7 pA for control (n = 51); 296.5 ± 52.5 
pA for 32.5 M MCD/7DHC (n = 7), p = 0.002; 300.0 ± 37.4 pA 65 M MCD/7DHC (n = 
11), p = 0.003; 174.8 ± 9.1 pA for 195 M MCD/7DHC (n = 11), p<0.001). Consequently, 
the MCD/7DHC loading significantly decreased the current density of Kv1.3 of T cells 
unlike for those from the SLOS patients (CuD was 282.5 ± 42.9 pA/pF for control (n = 51); 
153.0 ± 44.8 pA/pF for 32.5 M (n = 7) p = 0.005; 176.9 ± 26.5 pA/pF for 65 M (n = 11), p 
= 0.002; and 81.9 ± 8.9 pA/pF for 195 M, p<0.001, (n = 11).  
IV.13. Comparison of CHOL and 7DHC loading 
In our previous study we demonstrated that in vitro loading of CHOL slowed the kinetics and 
modified the steady-state parameters of Kv1.3 gating. Similar changes in the biophysical 
parameters of Kv1.3 gating were found in the current study in SLOS and SLO model system. 
These results raised the question whether the effect of 7DHC and CHOL loading are 
quantitatively similar or different. Therefore, we treated the T cells with the same 
concentration of CHOL and 7DHC and measured the biophysical properties of Kv1.3. We 
found that Kv1.3 is more sensitive to 7DHC than CHOL loading at 32.5µM: 7DHC 
significantly increased the activation time constant and shifted V1/2 towards positive voltages, 
whereas CHOL did not (a = 0.59 ± 0.02 ms for control (n = 56); 0.75±0.15 ms for 32.5 M 
MCD/CHOL (n = 5), p = 0.40; 1.76±0.18 ms for 32.5 M MCD/7DHC (n = 5), 
p<0.001;V1/2 = −26.9 ± 0.9 mV for control (n = 41); −24.4 ±3.1 mV for 32.5 M 
MCD/CHOL (n = 5), p = 0.318; and −19.2 ± 1.3 mV for 32.5 μM MCD/7DHC (n = 6), p = 
0.004). At higher concentrations of MCD/7DHC and MCD/CHOL both compounds 
changed the kinetic and steady state parameters of Kv1.3 gating but 195 µM MCD/7DHC 
was more effective in changing V1/2 than equimolar MCD/CHOL (V1/2  = −17.4 ±0.58 mV 
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for 65 μM MCD/CHOL(n = 5), p = 0.29; and −13.4±2.6 mV for 65 μM MCD/7DHC 
(n=5), p = 0.024; −16.2 ± 2.72 mV for 195μM MCD/CHOL (n = 5), p = 0.038; and −10.1 ± 
1.9 mV for 195 μM MCD/7DHC (n=5), p<0.001; a = 0.99 ± 0.09 ms for 65 μM 
MCD/CHOL (n=5), p = 0.059; and 2.04 ± 0.15 ms for 65 μM MCD/7DHC (n = 5), 
p<0.001;1.05±0.09 ms for 195μM MCD/CHOL(n = 5), p = 0.02; and 2.62 ± 0.22 ms for 195 
μM MCD/7DHC(n = 5), p<0.001).  
IV.14. Removal of the cytoplasmic C-terminal of Kv1.3: loss of sensitivity to sterol 
loading 
We tested the effect of CHOL and 7DHC loading on a C-terminal-deleted Kv1.3 channel 
(mGFP-Kv1.3ΔC), which lacks the last 84 amino acid residues at its C-terminal and 
consequently lacks the two CARC sequences recently identified on other ion channels as 
specific CHOL receptor sites being responsible for the effect of sterols on ion channels. 
Previously we showed that biophysical characteristics of the Kv1.3-WT and Kv1.3ΔC are 
identical, removal of the C-terminal did not change significantly gating properties of Kv1.3. 
After that Kv1.3-WT and Kv1.3ΔC expressing CHO cells were loaded using 420M CHOL 
and 7DHC, and ionic currents were measured in outside-out patch configuration. As expected 
420M CHOL or 7DHC shifted the midpoint of the voltage-dependence of steady-state 
activation and increased the activation time constant in case of the mGFP-Kv1.3-WT CHO 
cells (V1/2,WT: −28.87±1.52 (n = 5) for control and −17.45±1.90 mV for 420 M CHOL (n = 
7), p<0.001; −19.25±4.72 mV (n = 5), p = 0.028 for 420 M 7DHC; a,WT: 0.45±0.014 ms for 
control (n = 5), 0.76±0.022 ms for 420 M MCD/CHOL (n = 7) p = 0.002; 0.69±0.059 ms 
for 420M MCD/7DHC (n = 10) p = 0.008). On the contrary, mGFP-Kv1.3ΔC channels 
were insensitive to both CHOL and 7DHC loading (V1/2,ΔC:−26.73±2.72 mV for control (n = 
6); V1/2,ΔC:−26.30±2.72 mV for 420 M MCD/CHOL (n = 8), p>0.05; V1/2,ΔC: −23.05±1.08 
mV for 420 M MCD/7DHC (n = 6), p>0.05); and a,ΔC: 0.59±0.043 ms for control (n = 6), 
0.55±0.022 ms for 420M MCD/CHOL (n = 7), p>0.05; 0.65±0.036 ms for 420M 
MCD/7DHC (n = 10), p>0.05). Intracellular C-terminus is less sensitive to the changes of 
the physical properties of the cell membrane relative to transmembrane regions. Based on this, 
we assumed that cholesterol could affect the gating of Kv1.3 not only via regulating physical 
properties of the cell membrane but also creating specific lipid-protein interactions. Scanning 
through the C-terminus of Kv1.3 we could identify two potential cholesterol recognition sites 
(CARC1 and CARC2). To study the significance of these motifs we changed the key amino 
22 
 
acid residues to alanine. (In case of the Kv1.3CARC1  474lysine, 479tyrosine and 479valine 
while in mKv1.3CARC2 517lysine, 518lysine, 520phenylalanine, 523valine were mutated to 
alanine.) As we expected based on the biophysical characteristics of the Kv1.3ΔC channel, 
Kv1.3CARC1 and mKv1.3CARC2 had similar gating properties as compared to the wild-type 
Kv1.3. Then we loaded the transfected CHO cells with 420M CHOL or 7DHC and  
determined the biophysical properties of mKv1.3CARC1 and mKv1.3CARC2. Point mutations 
have changed the sterol sensitivity of the mutated channels. In the case of mKv1.3CARC1 the 
steady-state activation shifted rightward while the activation kinetics did not alter upon 
cholesterol loading. The same amount of 7DHC loading significantly increased the activation 
time constant and the half-maximal voltage of the steady state activation (V1/2, control: 
−26.37±1.6 (n = 8) for control and −17.09±2.27 mV for 420 M CHOL (n = 8), p=0.005; 
−18.89±1.94 mV (n = 3), p = 0.03 for 420 M 7DHC; a,control: 0.57±0.03 ms for control (n = 
14), 0.63±0.04 ms for 420 M MCD/CHOL (n = 14) p = 0.248; 0.98±0.06 ms for 420M 
MCD/7DHC (n = 3) p = 0.001). The cholesterol loading slowed the activation kinetics of 
mKv1.3CARC2 but it did not alter the steady-state activation.  The 7DHC treatment caused 
similar changes that we found in case of the wild type channel. (V1/2, control: −26.45±3.3 (n = 5) 
for control and −24.26±2.27 mV for 420 M CHOL (n = 9), p=0.59; −16.23±1.61 mV (n = 
5), p = 0.024 for 420 M 7DHC; a,control: 0.44±0.01 ms for control (n = 11), 0.63±0.04 ms for 
420 M MCD/CHOL (n = 14) p = 0.001; 1.59±0.31 ms for 420M MCD/7DHC (n = 5) p 
< 0.001). 
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V. SUMMARY 
Cholesterol is an essential component of the cell membrane and involved in the 
syntheses of many bioactive molecules. Hypercholesterinemia, which is characterized by the 
abnormally elevated serum cholesterol level, is a frequent dyslipidemia. Inborn errors of 
cholesterol synthesis (e.g. Smith-Lemli-Opitz syndrome, SLOS) are rare, genetic disorders 
with pathognomonic low cholesterol and increased cholesterol precursor serum levels. In vitro 
manipulation of the membrane cholesterol of T cells modifies the gating parameters of the 
essential voltage-gated Kv1.3 channel, however a comprehensive study that confirms the 
pathophysiological significance of these results is missing. Therefore we isolated lymphocytes 
from patient with SLOS and hypercholesterinemia to study the consequence of in vivo altered 
membrane cholesterol composition on Kv1.3 channel and T lymphocyte function. To expand 
our knowledge about the interaction of sterols with Kv1.3 we searched for the existence of 
cholesterol recognition sites in an in vitro modified sterol environment. Our results indicated 
that hypercholesterinemia just slightly altered the Kv1.3 function unlike in our previous study 
where in vitro cholesterol loading had remarkable effects. The reason of this could be that the 
cholesterol content of the cells in hypercholesterolemia is not as high as in the in vitro model 
systems. This is supported by the data obtained in a patient with extreme high cholesterol 
level: changes in Kv1.3 biophysical parameters were comparable to those described for the in 
vitro loaded T cells. The proliferation capacity of the T cells decreased regardless of the lack 
in the Kv1.3 function.  
In SLOS the kinetics of Kv1.3 gating slowed down and the steady-state activation 
shifted toward positive potentials. Identical changes in Kv1.3 operation were observed when 
control/healthy T cell membrane was loaded with 7DHC. Functional assays exhibited 
impaired activation and proliferation rate of T cells probably partially due to the modified 
Kv1.3 operation. Removal of the putative sterol binding sites on Kv1.3 resulted in a 
phenotype that was not influenced by the elevation in membrane sterol level. We suppose that 
in hypercholesterinemia only the extreme high serum cholesterol levels influence biological 
functions of Kv1.3 significantly. We also concluded that the altered membrane sterol 
composition in SLOS hindered the operation of Kv1.3 as well as the ion channel-controlled T 
cell functions. We propose that the ion channel-sterol interaction described in our study 
reveals a molecular mechanism that may contribute to the pathophysiological conditions in 
SLOS, and may lead to the most prominent neurological and cardiovascular symptoms via 
influencing the physiological function of ion channels. 
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